Cite

    Liu, Z. et al. (2022). A randomized, double-blind, single-dose, parallel phase I clinical trial to compare the bioequivalence, immunogenicity, and safety of bevacizumab biosimilar and bevacizumab in healthy Chinese subjects. Expert opinion on drug metabolism and toxicology. pp. 519-527. [Online].